Eli Lilly Says New Long-Term Data From EBGLYSS Delivers Durable Skin Clearance And Relief From Persistent Itch For Up To Four Years For Patients With Eczema In Open-Label Extension Study Offering Once-Monthly Maintenance Injection

Eli Lilly and Company (NYSE: LLY) announced that its EBGLYSS treatment for moderate-to-severe atopic dermatitis has shown long-term efficacy, with nearly all patients achieving significant skin improvement (EASI-75) for up to four years. In the study, 75% of patients reached near-complete skin clearance (EASI-90), and 78% reported significant relief from itch. Additionally, 80% of patients maintained durable results without the use of topical corticosteroids. These findings will be presented at the American Academy of Dermatology Annual Meeting from March 27-31, 2026.